Prostate Adenocarcinoma Clinical Trial
Official title:
Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen
Verified date | February 2024 |
Source | Roswell Park Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies how well aspirin and rintatolimod with or without interferon-alpha 2b work in treating patients with prostate cancer before surgery. Aspirin may help to keep the prostate cancer from coming back. Rintatolimod may stimulate the immune system and interfere with the ability of tumor cells to grow and spread. Interferon-alpha 2b may improve the body's natural response to infections and may slow tumor growth. It is not yet known how well rintatolimod, aspirin, and interferon-alpha 2b work in treating patients with prostate cancer undergoing surgery.
Status | Suspended |
Enrollment | 30 |
Est. completion date | May 29, 2024 |
Est. primary completion date | May 29, 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed, localized prostate adenocarcinoma patients who are planning to have a radical prostatectomy. - Diagnostic prostate biopsy must have been obtained within 6 months patients who had biopsies at outside facilities may be eligible if tissue availability and adequacy can be confirmed by pathology. - Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Platelet >= 75,000/uL. - Hemoglobin >= 9 g/dL. - Hematocrit >= 27%. - Absolute neutrophil count (ANC) >= 1500/uL. - Creatinine < institutional upper limit of normal (ULN) OR creatinine clearance >= 50 mL/min for patients with creatinine levels greater than ULN. - Total bilirubin =< 1.5 X institutional ULN. - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 X institutional ULN. - Serum amylase and lipase =< 1.5 X institutional ULN. - Negative hepatitis panel for patients with a history of Hepatitis - Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure. Exclusion Criteria: - Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment. - Patients who received hormonal therapy, 5-alpha reductase inhibitors (such as finasteride, dutasteride), chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment. - Patients with active prostatitis. - Patients with active autoimmune disease or history of transplantation. - Patients with comorbid medical conditions that render them unfit for surgery. - Metastatic disease based on preoperative imaging. - Cardiac risk factors including: - Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within 3 months of signing consent - Patients with a New York Heart Association classification of III or IV. - History of upper and lower gastrointestinal ulceration, upper gastrointestinal bleeding, or perforation within the past 3 years. - History of bleeding disorders, known lesions at risk for bleeding, or history of recent clinically significant bleed or hemorrhage (<3months). - Prior allergic reaction or hypersensitivity to aspirin, or other nonsteroidal antiinflammatory drugs (NSAIDs). - Patients are ineligible if they plan on use of other NSAIDs at any dose during the trial. Patients who agree to stop regular NSAIDs are eligible and no wash out period is required. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Unwilling or unable to follow protocol requirements. - Any condition which in the investigator?s opinion deems the participant an unsuitable candidate to receive study drug. |
Country | Name | City | State |
---|---|---|---|
United States | Roswell Park Cancer Institute | Buffalo | New York |
Lead Sponsor | Collaborator |
---|---|
Roswell Park Cancer Institute | AIM ImmunoTech Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Count of tumor infiltrating CD8+ lymphocytes | This will be assessed by the increase in the total number of tumor infiltrating CD8+ T cells in the radical prostatectomy specimen (measured as cell density of CD8+ cell by immunohistochemistry), comparing Arm A versus Arm B versus Arm C. Will be natural log transformed prior to analysis. The primary analysis will consist of testing the single degree of freedom planned contrast at alpha = .10 that the 3 treatment means are in the ratio of 3:2:1 (contrast coefficients 3, -2, -1) for groups A, B and C, respectively groups. If this test rejects the null hypothesis of no group differences, will proceed to estimate group means and pairwise differences between groups with 90% confidence intervals. Non-overlapping confidence intervals will serve as evidence of differential treatment effects. | Up to 3 years | |
Secondary | Pathologic response | Spearman rank correlation coefficients will be used to estimate the correlation between CD8+ tumor infiltrate, pathologic response rate and prostate specific antigen (PSA) response. | Up to 3 years | |
Secondary | Number of patients with Surgical margin positivity | Up to 3 years | ||
Secondary | PSA response | Spearman rank correlation coefficients will be used to estimate the correlation between CD8+ tumor infiltrate, pathologic response rate and PSA response. | Up to 3 years | |
Secondary | Incidence of treatment-related adverse events | Will be evaluated with National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. | Up to 30 days post treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03796767 -
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT05735223 -
A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence
|
N/A | |
Recruiting |
NCT04175431 -
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
|
Phase 2 | |
Completed |
NCT05197257 -
68Ga-PSMA-11 PET in Patients With Prostate Cancer
|
Phase 3 | |
Withdrawn |
NCT03982173 -
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
|
Phase 2 | |
Terminated |
NCT02491411 -
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
|
N/A | |
Active, not recruiting |
NCT02254746 -
A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer
|
N/A | |
Active, not recruiting |
NCT05496959 -
177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
|
Phase 2 | |
Completed |
NCT02940262 -
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
|
Phase 3 | |
Recruiting |
NCT04391556 -
Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT03503643 -
Hemi-Gland Cryoablation for Prostate Cancer at UCLA
|
||
Recruiting |
NCT05832086 -
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
|
Phase 2 | |
Suspended |
NCT05064111 -
Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
|
||
Not yet recruiting |
NCT04031378 -
Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT02600156 -
Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors
|
N/A | |
Recruiting |
NCT05726292 -
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04423211 -
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
|
Phase 3 | |
Terminated |
NCT03718338 -
Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
|
||
Terminated |
NCT02564549 -
MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca
|
N/A |